Last updated on November 2019

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months


Brief description of study

The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo in preventing relapse of schizophrenia symptoms.

Clinical Study Identifier: NCT03351244

Find a site near you

Start Over

Fujita Health University Hospital

Aichi, Toyoake, Japan
8.76miles
  Connect »